Mounjaro vs. Zepbound
See how Mounjaro and Zepbound compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Mounjaro and Zepbound are both brand names for tirzepatide, but only Zepbound carries an FDA approval for weight loss and sleep apnea.
Both drugs use the identical injection schedule, starting at 2.5 mg once weekly and rising in steps to a maximum of 15 mg.
Because they are the same molecule, expect a similar side effect profile, with gastrointestinal symptoms being the most common complaint for both.
Mounjaro vs. Zepbound Drug Summary
Mounjaro
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medicine that activates both the GIP and GLP-1 hormone receptors. It is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. Doctors also prescribe it off-label for weight loss in people who do not have diabetes.
Zepbound
Zepbound is the brand name for the same drug, tirzepatide, given as a once-weekly injection under the skin. It is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It does not carry an approval for treating diabetes.
Mounjaro vs. Zepbound Side Effects
Mounjaro
Zepbound
Mounjaro vs. Zepbound Dosage
Mounjaro
Zepbound
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | If needed |
| Dose changes | 5 increases | As tolerated |
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Zepbound
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | If needed |
| Dose changes | 5 increases | As tolerated |
Mounjaro vs. Zepbound Indications
Mounjaro
Mounjaro's only FDA-approved use is blood sugar control in type 2 diabetes, for both adults and children 10 and older. Using it for weight loss without diabetes falls outside that approval, so this is an off-label use. Many prescribers still use it this way because it contains the same active ingredient as Zepbound.
Blood sugar control in adults with type 2 diabetes
Blood sugar control in children 10 and older with type 2 diabetes
Off-label: weight loss in adults without diabetes
Not approved for type 1 diabetes
Zepbound
Zepbound is FDA-approved for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and exercise. It also carries an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved to treat type 2 diabetes, even though it is the same molecule as Mounjaro.
Chronic weight management in adults with obesity
Chronic weight management in adults who are overweight with a related condition
Moderate-to-severe obstructive sleep apnea in adults with obesity
Not approved for type 2 diabetes blood sugar control
Mounjaro vs. Zepbound Pros and Cons
Mounjaro
Mounjaro has the longer track record, having launched for diabetes in 2022, two years before its sister drug arrived for weight loss. Its FDA approval only covers blood sugar control, so insurers may push back if it is prescribed purely for weight loss. It is also the only tirzepatide product with a pediatric indication.
Pros
FDA-approved for type 2 diabetes, which gives it an established insurance billing pathway
Only tirzepatide product approved for children 10 and older with type 2 diabetes
Longer real-world safety track record since its 2022 approval
Cons
Using it for weight loss alone is off-label, so insurers may deny coverage for that purpose
No approved indication for obstructive sleep apnea
Prescribing for weight loss often requires a diabetes diagnosis to justify insurance coverage
Zepbound
Zepbound was built specifically for weight loss and sleep apnea, so its FDA labeling and insurance coding are made for those uses rather than diabetes. It comes in the same six dose strengths as Mounjaro, letting clinicians fine-tune a maintenance dose based on weight-loss response. It has no pediatric approval and is not intended for blood sugar management.
Pros
FDA-approved specifically for chronic weight management, giving it a dedicated obesity billing code
Also approved for moderate-to-severe obstructive sleep apnea, a use Mounjaro does not have
Dosing is tailored around weight-loss response rather than a diabetes-driven schedule
Cons
Not approved for blood sugar control, so people with diabetes are typically prescribed Mounjaro instead
No pediatric approval at any age
Some plans that exclude weight-loss drugs may deny it despite the obesity-specific approval
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.